Heart Disease Kills 1.7M Europeans Every Year, EMA Reports
During a media briefing addressing human pharmaceuticals in 2025, Francesca Day stressed that these conditions drive substantial disability rates, premature workforce exits, and workplace absences while devastating quality of life and longevity.
"Cardiovascular diseases remain the leading cause of death in Europe, with 1.7 million lives lost every year," she said.
Day pointed to escalating risk indicators throughout the region: 54% of adults carry excess weight, one in three youth battle overweight or obesity, and hypertension afflicts 25% of the population.
Addressing cardiometabolic conditions, Day explained the EMA prioritizes pharmaceuticals preventing and combating cardiac illness, alongside treatments for interconnected disorders including diabetes and obesity. Approximately 2.2 million EU residents live with type 1 diabetes, she added.
She underscored surging public attention toward GLP-1 receptor agonists—medications treating type 2 diabetes and controlling obesity through blood sugar reduction and appetite suppression.
"These medicines are not lifestyle shortcuts. They are long term treatments and they require medical supervision. Misuse and overuse of these medicines are real concerns," she warned.
The EMA greenlit 104 novel medications for market authorization in 2025, featuring 38 containing previously unapproved active substances within the EU.
Notable rare disease approvals included the inaugural treatment for Wiskott-Aldrich syndrome—a hereditary immune deficiency—and groundbreaking gene therapy for dystrophic epidermolysis bullosa, a disorder causing severely fragile skin.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
